Tenapanor (Ibsrela)
Small molecule
Evidence outlook
Approved: Irritable Bowel Syndrome with Constipation
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- IBSRELA (tenapanor) for irritable bowel syndrome with constipation in adults (Knight release dated 2020-04-17)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
T3MPO-1 NCT02621892 · Constipation Predominant Irritable Bowel Syndrome The study randomly assigned 606 participants to tenapanor or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary clinical responder endpoint was met in favor of tenapanor, with 83 of 307 participants responding versus 56 of 299 on placebo (p<0.02). Registry: NCT02621892 | 3 | 6 of 12 Week Overall Responder Rate (12 weeks) 2017-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
View 1 more trial
T3MPO-2 NCT02686138 · Constipation Predominant Irritable Bowel Syndrome The trial randomly assigned 593 participants to tenapanor or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was a clinically relevant combined bowel-movement and abdominal-pain response, and the comparison favored tenapanor with statistical significance (107/293 vs 71/300; p<0.001). Registry: NCT02686138 | 3 | Percentage of Subjects With Overall Response for 6 Out of 12 Weeks (First 12 weeks) 2017-08 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Competitive landscape
Other NHE3 (sodium/hydrogen exchanger isoform 3) drugs
Tenapanor (Xphozah). Compare all 2 NHE3 (sodium/hydrogen exchanger isoform 3) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Irritable Bowel Syndrome with Constipation: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tenapanor (Ibsrela): this drug | Approved | Small molecule | NHE3 (sodium/hydrogen exchanger isoform 3) | Reliable signal | No reviewed efficacy summary in this indication | |
| Linaclotide (Linzess) | Approved | Peptide | Guanylate cyclase-C (GC-C) | Weak signal | NCT03573908: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period (Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)): Placebo -1.182 score on a scale (Standard Error 0.109) | Linaclotide 290 µg -1.898 score on a scale (Standard Error 0.111) | |
| Tenapanor (Xphozah) | Approved(overall) | Small molecule | NHE3 (sodium/hydrogen exchanger isoform 3) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 3(overall) | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tenapanor (Ibsrela) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.